SHORT MINI-FUTURE - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 13:43:15 2024-05-15 EDT | ||
| 3.46 EUR | -0.57% |
|
| Current month | -1.42% | ||
| 1 month | +10.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-15 | 3.46 | -0.57% |
| 24-05-14 | 3.48 | +0.87% |
| 24-05-13 | 3.45 | -0.86% |
| 24-05-10 | 3.48 | -1.42% |
| 24-05-09 | 3.53 | -1.94% |
Delayed Quote Deutsche Boerse AG
Last update May 15, 2024 at 01:43 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU0QS9 |
| ISIN | DE000VU0QS90 |
| Date issued | 2022-12-12 |
| Strike | 82.26 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.6 € |
|---|---|
| Lowest since issue | 0.46 € |
| Spread | 0.01 € |
| Spread % | 0.29% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
44.71
USD
Average target price
53.19
USD
Spread / Average Target
+18.98%
- Stock Market
- Certificates
- Certificat
